Gut bacteria are to blame for the failure of immune checkpoint therapy for ovarian cancer, new research reveals.

University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer ...

University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer by discovering how gut bacteria interfere with the treatment.

UVA Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer by discovering how gut bacteria interfere with the treatment.

University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer by discovering how gut ...

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparatopic antibody-drug ...

While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...

February marks Cancer Prevention Awareness Month, and local doctors are stressing the importance of early detection and prevention for two cancers that impact women: cervical and ovarian cancer.

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

February marks Cancer Prevention Awareness Month, and local doctors are stressing the importance of early detection and prevention for two cancers that impact women: cervical and ovarian cancer.

Researchers from Rice University and Baylor College of Medicine have developed a new treatment that eliminates advanced-stage ...